Transactions
16
Insider / QUEST DIAGNOSTICS INC
KUPPUSAMY KARTHIK
SVP, Clinical Solutions at QUEST DIAGNOSTICS INC
- Company
- QUEST DIAGNOSTICS INC
- Ticker
- DGX
- First filing on record
- October 24, 2025
- Latest trade on record
- July 22, 2026
- SEC filings
- EDGAR ↗
KUPPUSAMY KARTHIK, SVP, Clinical Solutions at QUEST DIAGNOSTICS INC, has disclosed 16 transactions in DGX since October 24, 2025: 0 purchases (0 open-market buys) and 5 sales, worth about $5.6M at the reported prices. The latest was filed July 27, 2026, 5 days after the trade; 2 filings were late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
5
Avg. disclosure lag
4.3d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months KUPPUSAMY KARTHIK made no purchases and 5 sales worth $2.3M, plus 10 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
KUPPUSAMY KARTHIK has traded 1 stock on record; the largest by dollars is DGX.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
2 of 7 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 4 | 18,203 | $1.3M |
| M | Option exercise or conversion | 4 | 16,294 | $2.0M |
| F | Shares withheld for tax | 3 | 716 | $149K |
| L | Small acquisition | 3 | 92 | $18K |
| S | Open-market sale | 2 | 10,775 | $2.2M |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 15 | 0 | 5 · $2.3M |
| 2025 | 1 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| DGX | Other L | July 22, 2026 | July 27, 2026 | 5d | 37 | $207 | $7,652 | late | Form 4 ↗ | |
| DGX | Option / conversion M | June 4, 2026 | June 8, 2026 | 4d | 4,827 | $122 | $588K | 10b5-1 planderivative | Form 4 ↗ | |
| DGX | Option / conversion M | June 4, 2026 | June 8, 2026 | 4d | 3,320 | $128 | $424K | 10b5-1 planderivative | Form 4 ↗ | |
| DGX | Sell S | June 4, 2026 | June 8, 2026 | 4d | 8,147 | $200 | $1.6M | 10b5-1 plan | Form 4 ↗ | |
| DGX | Option / conversion M | June 4, 2026 | June 8, 2026 | 4d | 4,827 | $122 | $588K | 10b5-1 plan | Form 4 ↗ | |
| DGX | Option / conversion M | June 4, 2026 | June 8, 2026 | 4d | 3,320 | $128 | $424K | 10b5-1 plan | Form 4 ↗ | |
| DGX | Other L | April 20, 2026 | April 24, 2026 | 4d | 39 | $195 | $7,593 | Form 4 ↗ | ||
| DGX | Sell S | March 4, 2026 | March 6, 2026 | 2d | 2,628 | $205 | $538K | Form 4 ↗ | ||
| DGX | Other A | March 4, 2026 | March 6, 2026 | 2d | 6,200 | $205 | $1.3M | Form 4 ↗ | ||
| DGX | Sell F | March 2, 2026 | March 4, 2026 | 2d | 205 | $205 | $42K | Form 4 ↗ | ||
| DGX | Other A | February 18, 2026 | February 20, 2026 | 2d | 9,853 | — | — | derivative | Form 4 ↗ | |
| DGX | Other L | January 28, 2026 | February 20, 2026 | 23d | 16 | $184 | $2,936 | late | Form 4 ↗ | |
| DGX | Other A | February 18, 2026 | February 20, 2026 | 2d | 2,135 | — | — | Form 4 ↗ | ||
| DGX | Sell F | February 18, 2026 | February 20, 2026 | 2d | 259 | $207 | $54K | Form 4 ↗ | ||
| DGX | Sell F | February 18, 2026 | February 20, 2026 | 2d | 252 | $210 | $53K | Form 4 ↗ | ||
| DGX | Other A | October 21, 2025 | October 24, 2025 | 3d | 15 | $189 | $2,836 | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| July 27, 2026 | Form 4 | 0001022079-26-000086 | 1 | published | EDGAR ↗ |
| June 8, 2026 | Form 4 | 0001022079-26-000053 | 5 | published | EDGAR ↗ |
| April 24, 2026 | Form 4 | 0001022079-26-000045 | 1 | published | EDGAR ↗ |
| March 6, 2026 | Form 4 | 0001022079-26-000025 | 2 | published | EDGAR ↗ |
| March 4, 2026 | Form 4 | 0001022079-26-000019 | 1 | published | EDGAR ↗ |
| February 20, 2026 | Form 4 | 0001955217-26-000002 | 5 | published | EDGAR ↗ |
| October 24, 2025 | Form 4 | 0001022079-25-000229 | 1 | published | EDGAR ↗ |
Other insiders at QUEST DIAGNOSTICS INC
- DELANEY MARK E SVP & Chief Commercial Officer 17 rows
- Doherty Catherine T. EVP, Regional Businesses 17 rows
- Plewman Patrick SVP for Diagnostic Services 17 rows
- Davis J. E. CEO and President 16 rows
- PREVOZNIK MICHAEL E SVP & General Counsel 16 rows
- SAMAD SAM Executive Vice President & CFO 13 rows
- Lassiter Wright III Director 11 rows
- Deppe Michael J SVP, Corp. Controller & CAO 7 rows
- Gregg Vicky B Director 6 rows
- CARTER ROBERT B Director 5 rows
Everyone on file, with contracts and lobbying under the company's name: QUEST DIAGNOSTICS INC.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 7 | 16 | October 24, 2025 | July 27, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.